A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy (STELLAR Study)

Better treatment options are needed for patients with recurrent anaplastic astrocytoma (or rAA).
The purpose of the STELLAR trial is to study eflornithine oral solution as a possible new treatment for patients with rAA, and the trial is now open for enrollment.
In the STELLAR trial, patients with rAA will receive treatment with either eflornithine in combination with lomustine, or lomustine by itself. Patients are randomly assigned to one of the two treatment groups. Treatment lasts up to 12 or 24 months, depending on the treatment group. Treatment is followed by an observation period for up to 24 months.

Participate in a Clinical Trial

Learn More